tiprankstipranks
Trending News
More News >
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
Australian Market

Vectus Biosystems Limited (VBS) AI Stock Analysis

Compare
2 Followers

Top Page

AU

Vectus Biosystems Limited

(Sydney:VBS)

Rating:38Underperform
Price Target:
AU$0.00
▼(-100.00%Downside)
Vectus Biosystems Limited has a low overall stock score due to severe financial underperformance, bearish technical indicators, and an unattractive valuation. The company's financial instability and lack of earnings present significant risks.

Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)

Vectus Biosystems Limited Business Overview & Revenue Model

Company DescriptionVectus Biosystems Limited (VBS) is an Australian biotechnology company specializing in the development of therapeutic treatments for fibrotic diseases and hypertension. The company's core product pipeline includes a series of novel small molecule drugs targeting fibrotic conditions, such as liver, cardiac, and renal fibrosis, as well as treatments for high blood pressure. Vectus Biosystems leverages its proprietary technology platform to address unmet medical needs in the field of fibrosis and cardiovascular health.
How the Company Makes MoneyVectus Biosystems Limited makes money primarily through the development and commercialization of its pharmaceutical products aimed at treating fibrotic diseases and hypertension. The company's revenue model includes licensing agreements with larger pharmaceutical companies for its drug candidates, securing milestone payments upon reaching specific development stages, and receiving royalties on product sales once the drugs are marketed. Additionally, Vectus may engage in collaborative research and development partnerships, which can provide financial support and share the risk of drug development. The company's financial success is significantly influenced by the progress of its drug candidates through clinical trials and regulatory approvals, as well as the potential for successful commercialization of its products.

Vectus Biosystems Limited Financial Statement Overview

Summary
Vectus Biosystems Limited is facing significant financial challenges, with declining revenues, persistent losses, and negative equity. Despite some improvement in cash flow, the overall financial health remains weak, requiring strategic initiatives to enhance revenue and manage costs.
Income Statement
40
Negative
Vectus Biosystems Limited has demonstrated a declining revenue trend with a negative revenue growth rate from 2023 to 2024. The company is struggling with profitability, reflected in negative net profit and EBIT margins. Despite some gross profit, the overall financial performance remains weak due to high operating losses.
Balance Sheet
35
Negative
The balance sheet shows a significant improvement in debt levels, but the company still faces challenges with negative equity, indicating long-term financial instability. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio remains negative, undermining financial stability.
Cash Flow
45
Neutral
The cash flow statement highlights negative operating and free cash flows, with slight improvement in free cash flow from the previous year. The company exhibits a weak operating cash flow to net income ratio, indicating inefficient cash conversion from operations.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue884.21K1.14M1.35M1.30M180.0051.19K
Gross Profit884.21K1.14M1.31M1.28M1.02M31.67K
EBITDA-2.14M-2.27M-3.19M-3.28M-3.71M-2.64M
Net Income-2.26M-2.34M-3.45M-3.99M-3.86M-3.00M
Balance Sheet
Total Assets1.23M2.03M4.63M3.94M6.98M3.00M
Cash, Cash Equivalents and Short-Term Investments809.89K808.97K2.95M1.28M5.78M2.72M
Total Debt0.0028.93K70.21K6.90M8.68M8.28M
Total Liabilities830.77K539.26K1.11M8.36M9.88M9.71M
Stockholders Equity403.15K1.49M3.52M-4.42M-2.90M-6.71M
Cash Flow
Free Cash Flow-1.41M-2.10M-2.37M-4.46M-3.26M-3.00M
Operating Cash Flow-1.44M-2.03M-2.35M-4.44M-3.26M-3.00M
Investing Cash Flow268.04K-67.90K-17.13K-21.00K0.000.00
Financing Cash Flow-41.28K-41.28K4.04M-34.55K6.35M5.64M

Vectus Biosystems Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.04
Price Trends
50DMA
0.06
Negative
100DMA
0.07
Negative
200DMA
0.07
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
22.55
Positive
STOCH
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 22.55 is Positive, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
AU$2.49B4.37-64.25%2.83%36.51%13.14%
AU1AD
46
Neutral
AU$2.68M-392.18%34.26%
AUHXL
40
Underperform
AU$2.17M-45.96%-26.67%
AUVBS
38
Underperform
AU$2.02M-163.00%9.19%
AUBIT
36
Underperform
$2.65M-119.28%64.10%
AUANR
27
Underperform
AU$1.28M-147.32%26.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:VBS
Vectus Biosystems Limited
0.04
-0.04
-50.00%
AU:BIT
Biotron
0.01
-0.03
-71.79%
AU:1AD
AdAlta Ltd.
0.01
-0.02
-66.67%
AU:ANR
Anatara Lifesciences Ltd
0.01
-0.03
-75.00%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Issues Unquoted Options to Employees
Jun 27, 2025

Vectus Biosystems Limited announced the issuance of 75,000 unquoted options as part of an employee incentive scheme. This move is likely aimed at retaining talent and aligning employee interests with company growth, potentially impacting the company’s operational dynamics and stakeholder relations positively.

Vectus Biosystems Advances VB0004 Commercialization and Seeks Chinese Collaborations
Apr 30, 2025

Vectus Biosystems Limited has been actively advancing its commercialization efforts for its lead compound, VB0004, and other drug candidates, with a focus on potential collaborations in China. The company has validated VB0004’s safety profile in recent clinical trials and is exploring faster approval paths in China. Financially, Vectus has reduced operating costs and is seeking licensing opportunities to support further clinical studies, with cash-on-hand reported at $370,000 as of March 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 21, 2025